Kazia Executes Agreement To Commence GBM Agile Pivotal Study-PR Newswire APAC

Kazia Executes Agreement To Commence GBM Agile Pivotal Study-PR Newswire APAC

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participation in the GBM AGILE pivotal study in...

Read more: Kazia Executes Agreement To Commence GBM Agile Pivotal Study-PR Newswire APAC

More Articles …

  1. Cambridge Quantum Computing Announces Update to t|ket⟩™ Quantum Software Development Kit (Q-SDK)-PR Newswire APAC
  2. Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference
  3. Lumen Launches Managed Endpoint Detection and Response Service in Asia Pacific-PR Newswire APAC
  4. SBW) Smart Shelves for Autonomous Retail Drive Casino Groupe New Automated Store in Paris-PR Newswire APAC
  5. Mölnlycke launches new skin-friendly Biogel® surgical gloves to reduce the risk of allergic contact dermatitis for surgeons and nurses
  6. Nintex Completes Acquisition of K2 Software, Inc.-PR Newswire APAC
  7. Growth acceleration accompanied by 3.7% YoY margin expansion; revenue and margin guidance increased to 2%-3% in cc and 23%-24% respectively-PR Newswire APAC
  8. Planon signs partnership with MazeMap-PR Newswire APAC
  9. Exiger Announces Global Expansion of Exiger Intelligence-PR Newswire APAC
  10. Fondazione Prada Presents "Human Brains," A Multidisciplinary Project Dedicated To Brain Studies-PR Newswire APAC